St. Louis Financial Planners Asset Management LLC Sells 205 Shares of AbbVie Inc. (NYSE:ABBV)

St. Louis Financial Planners Asset Management LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,186 shares of the company’s stock after selling 205 shares during the quarter. AbbVie comprises approximately 2.1% of St. Louis Financial Planners Asset Management LLC’s investment portfolio, making the stock its 8th biggest holding. St. Louis Financial Planners Asset Management LLC’s holdings in AbbVie were worth $2,338,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ABBV. V Square Quantitative Management LLC boosted its stake in AbbVie by 939.1% during the 3rd quarter. V Square Quantitative Management LLC now owns 1,434 shares of the company’s stock worth $214,000 after acquiring an additional 1,296 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of AbbVie by 238.3% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 94,401 shares of the company’s stock worth $14,071,000 after purchasing an additional 66,500 shares in the last quarter. Mystic Asset Management Inc. grew its holdings in shares of AbbVie by 0.5% in the 3rd quarter. Mystic Asset Management Inc. now owns 15,816 shares of the company’s stock valued at $2,358,000 after buying an additional 75 shares during the period. Retirement Planning Co of New England Inc. increased its position in shares of AbbVie by 21.3% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 26,409 shares of the company’s stock valued at $3,936,000 after buying an additional 4,633 shares in the last quarter. Finally, Blue Investment Partners LLC raised its stake in AbbVie by 6.6% during the 3rd quarter. Blue Investment Partners LLC now owns 1,664 shares of the company’s stock worth $248,000 after buying an additional 103 shares during the period. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 target price on shares of AbbVie in a research note on Thursday. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Wednesday, June 5th. Piper Sandler raised their target price on shares of AbbVie from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Tuesday. BMO Capital Markets cut their price target on shares of AbbVie from $195.00 to $180.00 and set an “outperform” rating on the stock in a research note on Monday, April 29th. Finally, Guggenheim increased their price objective on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $179.64.

AbbVie Trading Down 0.9 %

Shares of NYSE:ABBV opened at $170.57 on Friday. The company’s 50-day moving average price is $163.89 and its two-hundred day moving average price is $166.64. AbbVie Inc. has a one year low of $130.96 and a one year high of $182.89. The company has a debt-to-equity ratio of 7.93, a current ratio of 0.94 and a quick ratio of 0.83. The stock has a market capitalization of $301.20 billion, a PE ratio of 50.61, a price-to-earnings-growth ratio of 2.19 and a beta of 0.60.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, May 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.05. The business had revenue of $12.31 billion for the quarter, compared to analyst estimates of $11.93 billion. AbbVie had a return on equity of 179.47% and a net margin of 11.02%. AbbVie’s revenue was up .7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.46 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 11.27 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be paid a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of 3.63%. AbbVie’s dividend payout ratio is presently 183.98%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.